Clinical Trial

A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis

Study acronym: Kirros
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to assess the safety of atezolizumab and bevacizumab, or atezolizumab alone, as first-line treatment in participants with unresectable, locally advanced or metastatic hepatocellular carcinoma (HCC) with Child-pugh B7 or B8 cirrhosis.
Protocol Amendment History 2 changes
critical Trial status changed: RECRUITING → ACTIVE_NOT_RECRUITING 2026-07-11
notable Trial sites reduced: 62 -> 59 locations 2026-07-11
Trial Details
NCT Number NCT06096779
Lead Sponsor Genentech, Inc.
Conditions Hepatocellular Carcinoma
Enrollment 30 participants
Start Date 2024-07-15
Primary Completion 2027-07-30 (estimated)
Study Completion 2027-12-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-10